92 related articles for article (PubMed ID: 20438541)
1. Labile plasma iron generation after intravenous iron is time-dependent and transitory in patients undergoing chronic hemodialysis.
Rangel EB; Espósito BP; Carneiro FD; Mallet AC; Matos AC; Andreoli MC; Guimarães-Souza NK; Santos BF
Ther Apher Dial; 2010 Apr; 14(2):186-92. PubMed ID: 20438541
[TBL] [Abstract][Full Text] [Related]
2. The effects of intravenous iron treatment on oxidant stress and erythrocyte deformability in hemodialysis patients.
Cavdar C; Temiz A; Yeniçerioğlu Y; Calişkan S; Celik A; Sifil A; Onvural B; Camsari T
Scand J Urol Nephrol; 2003; 37(1):77-82. PubMed ID: 12745750
[TBL] [Abstract][Full Text] [Related]
3. Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran.
Malindretos P; Sarafidis PA; Rudenco I; Raptis V; Makedou K; Makedou A; Grekas DM
Am J Nephrol; 2007; 27(6):572-9. PubMed ID: 17804904
[TBL] [Abstract][Full Text] [Related]
4. Safety of intravenous injection of iron saccharate in haemodialysis patients.
Sunder-Plassmann G; Hörl WH
Nephrol Dial Transplant; 1996 Sep; 11(9):1797-802. PubMed ID: 8918625
[TBL] [Abstract][Full Text] [Related]
5. Limited value of zinc protoporphyrin as a marker of iron status in chronic hemodialysis patients.
Canavese C; Grill A; Decostanzi E; Maddalena E; Barbieri S; Martina G; Fop F; Buglione E; Grechi D; David O; Saitta M; Piccoli G
Clin Nephrol; 2000 Jan; 53(1):42-7. PubMed ID: 10661481
[TBL] [Abstract][Full Text] [Related]
6. Maintenance of elevated versus physiological iron indices in non-anaemic patients with chronic kidney disease: a randomized controlled trial.
McMahon LP; Kent AB; Kerr PG; Healy H; Irish AB; Cooper B; Kark A; Roger SD
Nephrol Dial Transplant; 2010 Mar; 25(3):920-6. PubMed ID: 19906658
[TBL] [Abstract][Full Text] [Related]
7. Effects of intravenous iron on mononuclear cells during the haemodialysis session.
Martin-Malo A; Merino A; Carracedo J; Alvarez-Lara MA; Ojeda R; Soriano S; Crespo R; Ramirez R; Aljama P
Nephrol Dial Transplant; 2012 Jun; 27(6):2465-71. PubMed ID: 22207322
[TBL] [Abstract][Full Text] [Related]
8. Effect of intravenous iron supplementation on hepatic cytochrome P450 3A4 activity in hemodialysis patients: a prospective, open-label study.
Pai AB; Norenberg J; Boyd A; Raj D; Chan LN
Clin Ther; 2007 Dec; 29(12):2699-705. PubMed ID: 18201586
[TBL] [Abstract][Full Text] [Related]
9. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.
Toblli JE; Lombraña A; Duarte P; Di Gennaro F
J Am Coll Cardiol; 2007 Oct; 50(17):1657-65. PubMed ID: 17950147
[TBL] [Abstract][Full Text] [Related]
10. Long-term, low-dose, intravenous vitamin C leads to plasma calcium oxalate supersaturation in hemodialysis patients.
Canavese C; Petrarulo M; Massarenti P; Berutti S; Fenoglio R; Pauletto D; Lanfranco G; Bergamo D; Sandri L; Marangella M
Am J Kidney Dis; 2005 Mar; 45(3):540-9. PubMed ID: 15754276
[TBL] [Abstract][Full Text] [Related]
11. Non-transferrin bound iron, cytokine activation and intracellular reactive oxygen species generation in hemodialysis patients receiving intravenous iron dextran or iron sucrose.
Pai AB; Conner T; McQuade CR; Olp J; Hicks P
Biometals; 2011 Aug; 24(4):603-13. PubMed ID: 21229380
[TBL] [Abstract][Full Text] [Related]
12. Lipid peroxidation products formation with various intravenous iron preparations in chronic kidney disease.
Ganguli A; Kohli HS; Khullar M; Lal Gupta K; Jha V; Sakhuja V
Ren Fail; 2009; 31(2):106-10. PubMed ID: 19212906
[TBL] [Abstract][Full Text] [Related]
13. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
14. Minor impairment of oral iron absorption in non-diabetic new dialysis patients.
Tovbin D; Schnaider A; Vorobiov M; Rogachev B; Basok A; Shull P; Novack V; Friger M; Avramov D; Zlotnik M
J Nephrol; 2005; 18(2):174-80. PubMed ID: 15931645
[TBL] [Abstract][Full Text] [Related]
15. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
16. Acute and subacute effects of EV iron sucrose on endothelial functions in hemodialysis patients.
Ozkurt S; Ozenc F; Degirmenci NA; Temiz G; Musmul A; Sahin G; Yalcin AU
Ren Fail; 2012; 34(1):1-6. PubMed ID: 22017464
[TBL] [Abstract][Full Text] [Related]
17. Use of ascorbate-rich dialysate to attenuate oxidative stress in maintenance hemodialysis patients.
Shi XF; Ding F; Zhu QY; Xue J; Lu FM; Gu Y; Lin ST
Ren Fail; 2005; 27(2):213-9. PubMed ID: 15807188
[TBL] [Abstract][Full Text] [Related]
18. Intravenous iron sucrose changes the intraperitoneal homeostasis.
Breborowicz A; Połubinska A; Kupczyk M; Wanic-Kossowka M; Oreopoulos DG
Blood Purif; 2009; 28(1):53-8. PubMed ID: 19325240
[TBL] [Abstract][Full Text] [Related]
19. The effect of long-term intravenous high dose B-complex vitamins with or without folic acid on serum homocysteine in hemodialysis patients.
Sombolos K; Fragia T; Natse T; Bartholomatos G; Karagianni A; Katsaris G; Christidou F; Bamichas G; Stangou M; Papagalanis N
J Nephrol; 2002; 15(6):671-5. PubMed ID: 12495282
[TBL] [Abstract][Full Text] [Related]
20. Elevated hepatocyte growth factor levels at the beginning of high-flux hemodialysis are due to heparin administration.
Christidou F; Bamichas G; Galaktidou G; Fragidis S; Gionanlis L; Frangia T; Bischiniotis T; Sombolos K
Ren Fail; 2008; 30(9):861-4. PubMed ID: 18925524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
